am6545 and Albuminuria

am6545 has been researched along with Albuminuria* in 2 studies

Other Studies

2 other study(ies) available for am6545 and Albuminuria

Article	Year
Reversal of albuminuria by combined AM6545 and perindopril therapy in experimental diabetic nephropathy. British journal of pharmacology, 2018, Volume: 175, Issue:23 The endocannabinoid (EC) system has been implicated in the pathogenesis of diabetic nephropathy (DN). We investigated the effects of peripheral blockade of the cannabinoid CB. Renal functional parameters (albumin excretion rate, creatinine clearance), tubular injury, renal structure, both EC and CB receptor levels and markers of podocyte dysfunction, fibrosis and inflammation were studied in streptozotocin-induced DM treated for 14 weeks with vehicle, the ACE-inhibitor perindopril (2 mg·kg. CB. Peripheral CB Topics: Albuminuria; Animals; Diabetes Mellitus, Experimental; Diabetic Nephropathies; Male; Mice; Mice, Inbred C57BL; Morpholines; Perindopril; Pyrazoles; Receptor, Cannabinoid, CB1	2018
Dual therapy targeting the endocannabinoid system prevents experimental diabetic nephropathy. Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association, 2017, Oct-01, Volume: 32, Issue:10 The endocannabinoid system has been implicated in the pathogenesis of diabetic nephropathy (DN). We investigated the effect of combined therapy with AM6545, a 'peripherally' restricted cannabinoid receptor type 1 (CB1R) neutral antagonist, and AM1241, a cannabinoid receptor type 2 (CB2R) agonist, in experimental DN.. Renal function and structure, podocyte proteins and markers of both fibrosis and inflammation were studied in streptozotocin-induced diabetic mice treated for 14 weeks with vehicle, AM6545, AM1241 and AM6545-AM1241.. Single treatment with either AM6545 or AM1241 alone reduced diabetes-induced albuminuria and prevented nephrin loss both in vivo and in vitro in podocytes exposed to glycated albumin. Dual therapy performed better than monotherapies, as it abolished albuminuria, inflammation, tubular injury and markedly reduced renal fibrosis. Converging anti-inflammatory mechanisms provide an explanation for this greater efficacy as dual therapy abolished diabetes-induced renal monocyte infiltration and M1/M2 macrophage imbalance in vivo and abrogated the profibrotic effect of M1 macrophage-conditioned media on cultured mesangial cells.. 'Peripheral' CB1R blockade is beneficial in experimental DN and this effect is synergically magnified by CB2R activation. Topics: Albuminuria; Animals; Anti-Inflammatory Agents; Cannabinoid Receptor Agonists; Cannabinoid Receptor Antagonists; Cannabinoids; Cells, Cultured; Diabetes Mellitus, Experimental; Diabetic Nephropathies; Drug Combinations; Drug Evaluation, Preclinical; Male; Mice; Mice, Inbred C57BL; Morpholines; Neutrophil Activation; Podocytes; Pyrazoles	2017

Article

Year

Reversal of albuminuria by combined AM6545 and perindopril therapy in experimental diabetic nephropathy.

British journal of pharmacology, 2018, Volume: 175, Issue:23

The endocannabinoid (EC) system has been implicated in the pathogenesis of diabetic nephropathy (DN). We investigated the effects of peripheral blockade of the cannabinoid CB. Renal functional parameters (albumin excretion rate, creatinine clearance), tubular injury, renal structure, both EC and CB receptor levels and markers of podocyte dysfunction, fibrosis and inflammation were studied in streptozotocin-induced DM treated for 14 weeks with vehicle, the ACE-inhibitor perindopril (2 mg·kg. CB. Peripheral CB

Topics: Albuminuria; Animals; Diabetes Mellitus, Experimental; Diabetic Nephropathies; Male; Mice; Mice, Inbred C57BL; Morpholines; Perindopril; Pyrazoles; Receptor, Cannabinoid, CB1

2018

Dual therapy targeting the endocannabinoid system prevents experimental diabetic nephropathy.

Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association, 2017, Oct-01, Volume: 32, Issue:10

The endocannabinoid system has been implicated in the pathogenesis of diabetic nephropathy (DN). We investigated the effect of combined therapy with AM6545, a 'peripherally' restricted cannabinoid receptor type 1 (CB1R) neutral antagonist, and AM1241, a cannabinoid receptor type 2 (CB2R) agonist, in experimental DN.. Renal function and structure, podocyte proteins and markers of both fibrosis and inflammation were studied in streptozotocin-induced diabetic mice treated for 14 weeks with vehicle, AM6545, AM1241 and AM6545-AM1241.. Single treatment with either AM6545 or AM1241 alone reduced diabetes-induced albuminuria and prevented nephrin loss both in vivo and in vitro in podocytes exposed to glycated albumin. Dual therapy performed better than monotherapies, as it abolished albuminuria, inflammation, tubular injury and markedly reduced renal fibrosis. Converging anti-inflammatory mechanisms provide an explanation for this greater efficacy as dual therapy abolished diabetes-induced renal monocyte infiltration and M1/M2 macrophage imbalance in vivo and abrogated the profibrotic effect of M1 macrophage-conditioned media on cultured mesangial cells.. 'Peripheral' CB1R blockade is beneficial in experimental DN and this effect is synergically magnified by CB2R activation.

Topics: Albuminuria; Animals; Anti-Inflammatory Agents; Cannabinoid Receptor Agonists; Cannabinoid Receptor Antagonists; Cannabinoids; Cells, Cultured; Diabetes Mellitus, Experimental; Diabetic Nephropathies; Drug Combinations; Drug Evaluation, Preclinical; Male; Mice; Mice, Inbred C57BL; Morpholines; Neutrophil Activation; Podocytes; Pyrazoles

2017